Anavex encouraged by new sigma-1 receptor study that may explain therapeutic efficacy of ANAVEX 2-73 for Alzheimer's disease

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) has announced that the current issue of the peer-reviewed scientific journal PLOS ONE explains that sigma-1 receptor (Sig-1R) activity is involved in cellular survival by regulating and stabilizing a key cell stress sensor… Read & Research Alzheimer’s More

Leave a Reply